Clinical experience of prescribing regdanvimab to inpatients with a new coronavirus infection COVID-19 and a high risk of its unfavorable course
- 作者: Sergoventsev А.А.1, Patsenko М.B.1, Demyanenko А.V.2, Afonaskov О.V.2, Zelenov М.V.2, Pomogaibo B.V.2
-
隶属关系:
- Main Military Medical Directorate of the Ministry of Defense of the Russian Federation
- The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
- 期: 卷 343, 编号 6 (2022)
- 页面: 22-26
- 栏目: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/629901
- DOI: https://doi.org/10.52424/00269050_2022_343_6_22
- ID: 629901
如何引用文章
详细
The aim of the study is to establish the relationship between the prescription of regdanvimab in a group of patients with a new coronavirus infection COVID-19 older than 50 years and risk factors with the development of a severe course of the disease, the duration of inpatient treatment, and adverse events. The new antiviral drug regdanvimab is a monoclonal antibody directed against the receptor-binding domain of the spike protein of the SARS-Cov-2 virus. The retrospective study included data from 40 patients over 50 years of age hospitalized with mild COVID-19 and at high risk of severe disease. Early additional administration of regdanvimab to the main treatment prevents the progression of the disease, significantly (by 5.9 days) reduces the duration of inpatient treatment in the group of patients older than 50 years with risk factors for an unfavorable course of the disease, and is not accompanied by adverse reactions to the administration of the drug.
作者简介
А. Sergoventsev
Main Military Medical Directorate of the Ministry of Defense of the Russian Federation
编辑信件的主要联系方式.
Email: dav_73@list.ru
заслуженный врач РФ, кандидат медицинских наук, генерал-майор медицинской службы
俄罗斯联邦, MoscowМ. Patsenko
Main Military Medical Directorate of the Ministry of Defense of the Russian Federation
Email: dav_73@list.ru
заслуженный врач РФ, кандидат медицинских наук, полковник медицинской службы
俄罗斯联邦, MoscowА. Demyanenko
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: dav_73@list.ru
заслуженный врач РФ, кандидат медицинских наук, полковник медицинской службы
俄罗斯联邦, MoscowО. Afonaskov
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: dav_73@list.ru
заслуженный врач РФ, кандидат медицинских наук, полковник медицинской службы
俄罗斯联邦, MoscowМ. Zelenov
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: dav_73@list.ru
кандидат медицинских наук, полковник медицинской службы
俄罗斯联邦, MoscowB. Pomogaibo
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: dav_73@list.ru
кандидат медицинских наук, полковник медицинской службы
俄罗斯联邦, Moscow参考
- Временные методические рекомендации Министерства здравоохранения Российской Федерации. Версия 14 от 27.12.2021 г.
- Есипов А.В., Алехнович А.В., Абушинов В.В. COVID-19: первый опыт оказания медицинской помощи и возможные решения проблемных вопросов (Обзор) // Госпит. медиц.: наука и практика. – 2020. – № 1. – С. 5–9.
- Есипов А.В., Павлов А.И., Прохорчик А.А. и др. Возможности барицитиниба и тоцилизумаба в монотерапии и комбинированном лечении больных со среднетяжелым и тяжелым течением COVID-19. Часть I // Госпит. медиц.: наука и практика. – 2021. – Т. 4, № 3. – С. 61–68.
- Есипов А.В., Павлов А.И., Прохорчик А.А. и др. Возможности барицитиниба и тоцилизумаба в монотерапии и комбинированном лечении больных со среднетяжелым и тяжелым течением COVID-19. Часть II // Госпит. медиц.: наука и практика. – 2021. – Т. 4, № 4. – С. 46–51.
- Зайцев А.А., Савушкина О.И., Черняк А.В., Кулагина И.Ц., Крюков Е.В. Клинико-функциональная характеристика пациентов, перенесших новую коронавирусную инфекцию COVID-19 // Практич. пульмонол. – 2020. – № 1. – С. 78–81.
- Зайцев А.А., Чернов С.А., Стец В.В., Паценко М.Б., Кудряшов О.И., Чернецов В.А., Крюков Е.В. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре: Метод. реком. // Consilium Medicum. – 2020. – Т. 22, № 11. – С. 91–97.
- Крайнюков П.Е., Демьяненко А.В., Афонасков О.В., Гудантов Р.Б., Попов А.В., Диева Т.В. Опыт лечения тяжелой формы коронавирусной инфекции COVID-19 в центральном военном госпитале // Воен.-мед. журн. – 2020. – Т. 341, № 10. – С. 63–66.
- Стандарт диагностики и лечения новой коронавирусной инфекции (COVID-19) у военнослужащих Вооруженных Сил Российской Федерации. Версия 3 от 08.10.2021 г. / Под ред. Д.В.Тришкина. – М., 2021. – 64 с.
- Eom J.S., Ison M., Streinu-Cercel A. et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. Res. Sq. 2021. doi: 10.21203/rs.3.rs-296518/v1
- European Medicines Agency. Celltrion use of regdanvimab for the treatment of COVID-19: assessment report. 2021. https://www.ema. europa.eu/en/documents/referral/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf. Accessed 1 Oct 2021
- European Medicines Agency. EMA issues advice on use of regdanvimab for treating COVID-19. 2021. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19. Accessed 11 Oct 2021
- European Medicines Agency. EMA receives application for marketing authorisation for Regkirona (regdanvimab) for treating patients with COVID-19. 2021. https://www.ema.europa.eu /en/news/ema-receives-application-marketing-authorisation-regkirona-regdanvimab-treating-patients-covid-19. Accessed 11 Oct 2021.
- European Medicines Agency. EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19 [media release]. 24 Feb 2021. http://www.ema.europa.eu.
- Kim C., Ryu D.K., Lee J. et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein // Nat. Commun. – 2021. – Vol. 12, N 1. – P. 288.
- Kim J.Y., Jang Y.R., Hong J.H. et al. Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection // Clin. Ther. – 2021. doi: 10.1016/j.clinthera.2021.08.009
- Kim S.B., Kim J., Huh K. et al. Korean Society of Infectious Diseases/National Evidence-Based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients With COVID-19 // Infect. Chemother. – 2021. – Vol. 53, N 2. – P. 395–403. doi: 10.3947/ic.2021.0304
- Lee J.Y., Lee J.Y., Ko J.H. et al. Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease // Front. Immunol. – 2021. – Vol. 12. doi: 10.3389/fimmu.2021.773320.
- Syed Y.Y. Regdanvimab: First Approval // Drugs. – 2021. – Vol. 81. – P. 2133–2137.
- WHO. WHO Coronavirus (COVID-19) Dashboard. 2021. Available at: https://covid19.who.int/ (Accessed 19 October, 2021).
补充文件
![](/img/style/loading.gif)